1 Min Read
Feb 21 (Reuters) - Ironwood Pharmaceuticals Inc:
* Qtrly loss per share $0.09
* Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million.
* Qtrly non-gaap loss per share $0.12
* Ironwood Pharmaceuticals Inc - expects combined allergan and ironwood total 2017 marketing and sales expenses for linzess to be in range of $250 million to $280 million
* Q4 earnings per share view $-0.24, revenue view $76.9 million -- Thomson Reuters I/B/E/S
* Expects to use less than $100 million in cash for operations in 2017 Source text for Eikon: Further company coverage: